KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC.

Authors

Andreas Rimner

Memorial Sloan Kettering Cancer Center, New York, NY

Andreas Rimner , W. Victoria Victoria Lai , Raffaele Califano , Salma K. Jabbour , Corinne Faivre-Finn , Byoung Chul Cho , Terufumi Kato , Jinming Yu , Li Yu , Bin Zhao , Maria Catherine Pietanza , Lauren Averett Byers

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012.

First Author: Salma K. Jabbour

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.

First Author: Jacob Sands

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer.

First Author: Toon Van Gorp

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Randomized phase III study of first-line pembrolizumab plus pemetrexed/platinum followed by pembrolizumab and maintenance olaparib versus pemetrexed in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC): KEYLYNK-006.

First Author: Jhanelle Elaine Gray